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Pain can be experienced at every stage of cancer and its treatment (50% to 90%); about 19–39.1% of patients suffer 
from neuropathic pain and 75% from mixed pain. Due to different treatment strategy a proper diagnosis of pain is 
of high importance. Opioids with a pure agonist effect are used to treat moderate and severe nociceptive pain and 
adjuvant drugs in the first line treatment of neuropathic pain.
Tapentadol is the only centrally acting opioid that combines two mechanisms of action — mu-opioid receptor (MO-
R)-agonist and norepinephrine reuptake inhibitor (NRI) activities. This specificity of action particularly predisposes 
tapentadol for use in mixed pain as well as in the therapy of various pain syndromes, both in the mechanism of re-
ceptor and neuropathic pain. The indication for the use of tapentadol is the treatment of chronic pain of high severity 
in adults, which can be properly controlled only after the use of opioid analgesics.
In experimental and clinical studies, the efficacy and good safety profile of tapentadol was proofed, both in acute 
(somatic and visceral) and chronic pain syndromes, including neuropathic pain.
Most of the studies concern chronic non-cancer pain. In the present case, the aspect of the occurrence of mixed cancer 
pain in course of pancreatic cancer with coexisting chemotherapy-induced neuropathy (treated with gabapentin) 
is emphasized. Due to the lack of good visceral control the combined method was used with opioids i.e. fentanyl 
TTS and oxycodone. Neurolysis of the celiac plexus was performed, followed by followed by main opioid rotation 
for tapentadol PR, resulting in a reduction in basic (visceral and neuropathic pain), and a reduction in the severity of 
breakthrough pain episodes, which were controlled by rapid-acting transmucosal fentanyl.
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Introduction
Pain can be experienced at every stage of cancer and its 
treatment. The early implementation of appropriate analge-
sics and adjuvant drugs in accordance with recommenda-
tions of WHO analgesic ladder and the guidelines of panel 
of expert scientific societies allows to sufficiently control 
pain in most cases. In moderate to severe pain, opioids are 
used. When choosing the right opioid, one should take into 
account the mechanism and intensity of pain, the patient’s 
age, metabolism and confounding factors, co-morbidities, 
medication, psychological status, reaction to the previously 
used opioid and the history of drug abuse.
Potent opioids are usually classified by affinity for opioid 
receptors and divided into full agonists, partial agonists and 
agonist-antagonists.
The most frequently used are opioids from the group of 
pure agonists that do not have a definite maximum dose. 
Opioids that are partial agonists or agonist-antagonists 
have so-called ceiling effect. In Poland, the most commonly 
used partial agonist is buprenorphine (a partial agonist of 
the μ and δ opioid receptors and the κ receptor antagonist) 
which, when used in therapeutic doses, acts like a pure 
agonist without a ceiling effect for analgesia.
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In contrast to other opioids, buprenorphine has a ben-
eficial effect from the safety perspective of therapy (e.g. 
the risk of opioid overdose), a ceiling effect for respiratory 
depression. The maximum recommended dose of transder-
mal buprenorphine is 140 mcg/h.
Buprenorphine is a partial agonist with low intrinsic 
activity. Opioids included in agonist-antagonists (butor-
phanol, nalbuphine, pentazocine) act agonistically on one 
of the receptors (mainly μ) and antagonistically on others. 
None of these is currently used in the treatment of acute 
and chronic pain [1, 2].
The pure mu-opioid receptor (MOR) agonists are classi-
fied according to the number of Ki, determining the degree 
of affinity for the receptor (binding strength).
Opioids were divided into three groups due to the K va-
lue:
 — K(i) > 100 nM tramadol, codeine, meperidine, propoxy-
phene, pentazocine;
 — K(i) = 1–100 nM hydrocodone, oxycodone, dipheno-
xylate, alfentanil, methadone, nalbuphine, fentanyl, 
morphine;
 — K(i) < 1 nM butorphanol, levorphanol, oxymorphone, 
hydromorphone, buprenorphine, sufentanil [3].
The smaller the Ki value, the greater the affinity for the 
μ receptor.
The most common in the treatment of cancer pain are 
drugs with a pure agonist action in relation to the known 
types of opioid receptors (strong affinity for μ receptors and 
weak in relation to the κ and δ receptor).
Morphine and fentanyl are characterized by a similar 
profile of interaction with major classes of receptors. Meth-
adone is characterized by a strong interaction of the μ and 
δ receptors. Oxycodone shows the strongest affinity for 
κ receptors [1, 2, 4, 5].
The duration of action may be pharmacologically determi-
ned (receptor binding mode), e.g. levorphanol and methadone, 
or pharmaceutically (tablet structure, patch) in sustained rele-
ase formulations such as SR morphine, oxycodone, tapentadol 
PR, transdermal fentanyl, transdermal buprenorphine.
The side effects of opioids, which are most often clini-
cally observed: nausea, sedation, constipation, respiratory 
depression, are the effect of activation of opioid receptors. 
Less common side effects, such as myoclonus, hallucinations 
and disorientation, are not reversed after administration of 
pure antagonists. Treatment of these symptoms requires 
a reduction of the opioid dose or a change of preparation 
(rotation). Quetiapine, haloperidol, olanzapine and chlor-
promazine are also used in the treatment of hallucinations 
and myoclonus. Symptoms usually increase proportionally 
to the opioid dose, and partial or total rotation is usually 
necessary. Deciding on rotation, metabolic causes of symp-
toms, such as hyponatremia, hypercalcemia or metastases 
to CNS should be excluded.
Nausea and vomiting may occur in 10–40% of patients 
at the initial stage of treatment. Most patients develop tole-
rance to this symptom, some require periodic administration 
of antiemetics.
Constipation remains a persistent problem during the 
treatment with opioids. Therefore, the disorder does not 
develop the phenomenon of tolerance. In many cases of 
opioid-induced constipation an effective solution is partial 
or complete change to a preparation with a proven lower 
risk of this side effect. The solution to the problem may 
be the conversion of a hydrophilic opioid to a lipophilic 
opioid, e.g. buprenorphine, fentanyl. In persistent cases, a 
combination of an agonist and antagonist (acting locally at 
intestinal level) should be used — oxycodone with naloxone. 
The lack of an opioid with a favorable profile of side effects 
encourages the search for new analgesics, preferably with 
a different mechanism of action and high analgesic efficacy, 
while not exacerbating unpleasant side effects [1, 6–8].
Tapentadol
Tapentadol is the latest opioid preparation introduced 
for the treatment of chronic pain as a strong opioid of the 
third step of analgesic ladder. Originally, a fast-acting form 
was created, and then a long-acting (prolonged release, 
PR) formula was developed. Currently available in Poland 
doses of tapentadol PR are 50 mg, 100 mg, 150 mg, 200 mg 
and 250 mg.
Tapentadol, a centrally acting opioid with strong anal-
gesic effect due to the dual mechanism of action contained 
in one molecule. The binding strength is K(i) 0.1 M. It is a 
mu-receptor agonist that simultaneously blocks the re-
uptake of norepinephrine (NRI — noradrenaline reuptake 
inhibitor). The affinity for the μ-receptor is 50 times weaker 
than in the case of morphine [1, 9, 10].
The affinity for the other opioid receptors (opioid re-
ceptor — κ, opioid receptor δ, ORL1 — opioid receptor-like 
receptor) is lower than for the MOR receptor. The degree of 
inhibition of serotonin reuptake is considered to be negligi-
ble and neglected in the characteristics of drug action [10].
It is highly probable (studies on animal models) that in 
cases of acute pain an agonistic activity on MOR receptor 
predominates in relation to the inhibitory effect of NRI.
Similarly, rats and mice in vivo experiments show 
a strong effect of tapentadol (which is 2–3 times weaker 
than morphine) in acute nociceptive pain. It is believed that 
the NRI mechanism synergistically contributes to the overall 
analgesic effect of tapentadol. The NA inhibitory effect is 
probably more important in chronic pain [9].
In relation to oral morphine, the conversion rate 1:3.3 is 
most commonly used [1].
Tapentadol is mainly metabolized in the liver, in the glu-
curonidation process, to inactive glucuronides or sulphates, 
primarily to glucuronyl-O-tapentadol (55%). Tapentadol and 
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its metabolites are mainly excreted by the kidneys (99%) 
and 1% of the drug is excreted in the faeces. It is very limi-
ted metabolism with the involvement of cytochrome P450 
isoenzymes, which limits the potential of interactions of 
tapentadol with other drugs. It is most metabolized by 
CYP2C9, CYP2C19, CYP2D6. Tapentadol does not inhibit or 
excite any of the CYP isoforms [11].
Tapentadol exhibits in vivo efficacy in heat-induced hy-
peralgesia models with a minimum effective dose ED50. Its 
action in diabetic neuropathy is well-established.
It is believed that the total analgesic effect in cases of 
neuropathic pain results from the simultaneous activation 
of both mechanisms: MOR and NRI.
The antinociceptive effect of tapentadol is partially re-
versed by naloxone (the opioid portion of MOR), and the 
effect of the non-nociceptive mechanism can be reduced 
by administration of yohimbine, a α (alpha) 2-adrenergic 
blocker, affecting the sympathetic nervous system [9].
Inhibition of NA reuptake enhances the downstream 
pain-inhibiting pathway through α2-adrenergic receptors 
[10].
The moderate affinity to MOR opioid receptor and the 
demonstrated opioid-saving effect suggest that tapenta-
dol should elicit less side effects associated with the use 
of opioid drugs compared to classical agonists. Indeed, in 
the comparative studies of morphine-tapentadol, oxyco-
done-tapentadol, fentanyl-tapentadol, it was shown that 
tapentadol to a lesser extent induces nausea and vomiting, 
as well as the duration of these symptoms is significantly 
shorter. Adverse symptoms occur at higher doses and the 
threshold for triggering symptoms is 100 times higher for 
tapentadol than for morphine.
Tapentadol has a weaker inhibitory effect on intestinal 
peristalsis than the equivalent dose of morphine (assessed 
by means of intestinal transit time labeled with carbon) [12]. 
A lower risk of causing adverse reactions was confirmed in 
the Merker study (2012). In the meta-analysis, the incidence 
of vomiting and constipation was significantly lower in the 
group of patients receiving tapentadol compared to the oxy-
codone group [7], while tapentadol to a greater extent pro-
motes the occurrence of dryness in the mouth. Similar data 
were obtained by Mercadante, investigating the efficacy 
and tolerance of the drug among patients with cancer pain 
who had never received opioids (so-called opioid naive) [13].
According to available evidence, tapentadol inhibits 
the uptake of serotonin to a negligible extent, so it also has 
no side effects (constipation, nausea, vomiting, diarrhea) 
resulting from an increase in serotonin in the central and 
intestinal nervous system [10].
Neuropathic pain in the course of cancer
The latest definition of neuropathic pain accepted by 
the Committee on the Taxonomy of the International Asso-
ciation for the Study of Pain (IASP) states that neuropathic 
pain is pain caused by injury or illness of the somatosensory 
part of the nervous system. It is estimated that 50% to 90% 
of cancer patients experience pain during their lifetime [14]. 
Among them 19–39.1% suffer from neuropathic pain [15]. 
Early diagnosis of symptoms is particularly important due 
to a different treatment strategy as compare to nocicepti-
ve pain. Among numerous causes of neuropathic pain in 
the course of neoplastic disease, factors related to tumor 
growth as well as treatment methods are mentioned, for 
example radiation-induced plexopathy (RIP) or chemothe-
rapy-induced peripheral polyneuropathy (CIPN). There are 
less frequent reports of neuropathic pain in the abdominal 
cavity, which is why they are not recognized early enough. 
Mechanical causes include biliary obstruction, impaired in-
testinal obstruction, organ perforation, advanced colorectal 
cancer, intraperitoneal chemotherapy. In cases of sympa-
thetic plexus disorders, bladder dysfunction or orthostatic 
hypotension appear [14–16].
Pain in the course of pancreatic cancer may be visceral, 
somatic or neuropathic. It results from tissue damage, lo-
cal inflammation, infiltration or mechanical obstacles. The 
signals are conducted by sympathetic fibers constituting the 
innervation of the visceral plexus from the level of Th12-L2 
[17]. Feeling of paroxysmal stabbing or burning pain is so-
metimes confused with incidents of breakthrough pain. Pain 
intensifies at night, disrupts daytime activity and hinders 
basic functions such as dressing, washing, combing and 
rest at night. The relationship between clinically occurring 
symptoms and etiology is not always clear [14].
Case report
The patient aged 62 was treated for 6 months due to ino-
perable pancreatic cancer (adenocarcinoma ductale pancre-
atis G2) and received palliative chemotherapy. The patient 
was given 12 courses according to the FOLFIRNOX protocol: 
fluorouracil + calcium folinate + oxaliplatin + irinotecan. 
There were co-existing problems: arterial hypertension, 
hyperlipidemia, history of two prior myocardial infarctions 
(2011 and 2014) and coronary angioplasty. During the sub-
sequent courses of chemotherapy, the patient had grade I 
neutropenia.
Common side effects of FOLFIRNOX are: neutropenia, 
neutropenic fever, thrombocytopenia, sensory neuropathy 
(platinum derivatives), diarrhea.
The neoplastic lesion was located in the head of the 
pancreas. The patient reported epigastric pain radiating 
to the spine at Th10–12. In addition, there was a feeling of 
numbness and tingling in the hands and feet (greater in 
feet). Symptoms began to intensify after the eighth cycle of 
chemotherapy. It was a mixed type of pain, with a distinct 
neuropathic component, described as pulsating, squeezing 
and radiating to the back. The patient was diagnosed with 
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two neuropathic pain: the first one as a pancreatic compo-
nent, the second — peripheral polyneuropathy. Previous 
pharmacological treatment didn’t sufficiently controlled 
the pain. The patient assessed his present pain intensity in 
the VAS scale (0–100) on 80–90, with periodic exacerbations 
up to 100.
The initial diagnosis was: visceral pain within the abdo-
minal cavity in the course of pancreatic cancer, comorbid 
with pain of the nature of neuropathy in the hands and feet, 
with a feeling of numbness and tingling (complication after 
chemotherapy). The patient was referred by an oncologist to 
be qualified for interventional pain management (neurolysis 
of celiac plexus).
ECOG performance status was 2. The results of lab tests 
confirmed adequate liver and kidneys functions. Clinical 
symptoms of pre-cachexia have been observed, risk related 
to the nutritional status NRS (nutritional risk score) 2002 = 2.
Surgery was postponed due to the lack of sufficient 
assessment of the cardiac output — ejection fraction (EF). 
Heart failure is diagnosed below 50%, whereas with an EF 
of > 45%, there is a risk that the patient will have a fall in 
blood pressure following the expansion of the abdominal 
vascular bed.
The patient was admitted to establish analgesia. Drugs 
previously used were: oxycodone 60 mg b.i.d., fentanyl 
transdermal system 150 mcg/h every 3 days, morphine 
IR 20 mg PRN. Other medicines used: low molecular we-
ight heparin 40 mg/0.4 1 amp. q.d. s.c., spironolactone 25 
mg every other day, furosemide 40 mg q.d., metoprolol 25 
mg q.d., pancreatin 25 thousand U q.d. with a main meal, 
alprazolam 0,25  mcg b.i.d., ketoprofen duo1 table PRN, 
ketoprofen forte 100 mg b.i.d.
To extent the diagnosis, a CT scan of the abdominal cav-
ity was performed, which showed an advanced local cancer. 
In the area around the head of the pancreas, a solid-fluid 
lesion with approximate size 83 mm × 87 mm ×  70 mm 
was visible. The lesion adhered to the aorta and duodenum 
and infiltrated the initial segments of the celiac trunk and 
upper mesenteric artery. The Wirsung duct distal to the 
lesion was widened to approx. 7 mm. The body and tail of 
the pancreas were normal. Enlarged peripancreatic lymph 
nodes and several lymph nodes along the aorta and inferior 
vena cava up to 36 mm × 25 mm were observed. The liver 
was normal, with no focal lesions. Bones without visible 
secondary lesions.
The dose of oxycodone was increased to 200 mg/day 
(below the calculated equivalent dose) with rotating within 
3 days by 1/3 of daily dose. Fentanyl TTS was discontinued 
in two stages: reduction to 100 mcg/h and after another 
3 days to 50 mcg/h.
Slow rotation allows better tolerance of treatment 
change. Salvage Rescue therapy with morphine IR 20 mg 
p.o. was used to titrate a requirement for strong opioid and 
achieve satisfactory pain control, and lactulose 3 × 20 ml 
as prevention of constipation. Gabapentin 100 mg t.i.d. as 
co-analgetic was added, gradually increasing to 300 mg 
t.i.d. due to the diagnosis of CIPN. A satisfactory analge-
sic effect was obtained, however, after 4 days the patient 
reported increasing constipation. Stool with a hard con-
sistency appeared every 3–4 days, with flatulence, nausea 
and lack of appetite. In case of opioid-induced constipation 
constipation, conversion to another opioid with a lower 
risk of constipation should be considered. It was decided 
to convert a part dose of oxycodone daily dose (200 mg) 
to oxycodone with naloxone with the ratio 1/3 oxycodone 
with naloxone 60 mg/day and 2/3 oxycodone (140 mg/day). 
Instead of morphine IR INN-fentanyl buccal tablet should 
be considered, 400 mcg (after titration) was used to treat 
breakthrough pain, up to 4 times a day.
Lack of good analgesic effect, despite relatively high 
doses of opioid, may be caused by the increasing tolerance 
for a given opioid. The indication for conversion to another 
opioid is the development of tolerance, difficult to control 
adverse effects and unfavorable balance between analgesic 
effect and adverse effects.
Tolerance to opioids should be distinguished from the 
resistance of some types of pain to opioids (e.g. neuropathic 
pain). If the indication for rotation is the development of 
tolerance, or when the first opioid is used in high doses — 
treatment with the second opioid begins from 1/2–1/4 of 
the calculated equivalent dose. Tables with equivalent doses 
are only an example (guide) of how to calculate them, and 
they should be approached with caution.
Due to the lack of satisfactory pain control and increas-
ing opioid-induced constipation — after obtaining a posi-
tive echocardiography result (EF 49%) — neurolysis of the 
celiac plexus was performed. Good analgesic effect was 
obtained.
In subsequent days, the dose of oxycodone was re-
duced every 3 days depending on the situation, without 
changing the dose of gabapentin (3 × 300 mg). Due to the 
duration of episodes of visceral pain INN-fentanyl buccal 
tablet (200 mcg) was maintained as a rescue medicine. The 
patient achieved a reduction in primary pain intensity up 
to 50 according to VAS scale.
Nausea and periodic vomiting appeared again. Ab-
dominal X-ray revealed partial intestinal sub-obstruction. 
Conservative treatment was introduced: metoclopramide 
i.v., spasmolytic drugs i.v., dexamethasone i.v. Due to high 
dose of transdermal fentanyl previously taken (150 mcg/h) 
and lack of analgesic effect it seemed doubtful that the 
return to fentanyl TTS would be effective. In addition, due 
to peripheral edema and low molecular weight heparin 
taken, subcutaneous route would be associated with the 
formation of hematomas after injection and impaired ab-
sorption of the drug.
150
Over the next 4 days, analgesia was carried out with mor-
phine i.v. in a PCA (patient controlled analgesia) pump. The 
pump was equipped with a button, triggering the supply 
of the programmed dose of rescue medication whenever 
was pressed by the patient. The conversion dose: oxycodone 
200 mg = morphine 300 mg (conversion rate 1:1.5), 1/3 of 
the oral dose = 100 mg i.v. dose, which is 100 mg/24 h; and 
4.1 mg/h as a continuous infusion. In addition, a PCA 1 mg 
bolus was programmed with lockout time 15 min.
After controlling nausea and vomiting, morphine i.v. 
was changed to tapentadol PR p.o. The choice of opioid 
was guided by the nature of the discomfort (mixed pain), 
partial occurrence of receptor (visceral) pain and partly 
neuropathic pain (peripheral polyneuropathy). Tapentadol 
also has a much more favorable profile of gastrointestinal 
side effects vs other potent opioids (e.g. oxycodone, mor-
phine). The dose of tapentadol retard 200 mg b.i.d (less than 
equivalent) was included, keeping the INN-fentanyl buccal 
tablet 200 mgc as a rescue medicine. After the celiac plexus 
neurolysis and opioid re-rotation, the intensity of the basic 
pain stabilized at level 40 according to the VAS scale.
Final recommendations for pain management: tapen-
tadol retard 200 mg b.i.d., INN-fentanyl buccal tablet 
200 mcg/dose, not more than 4 times per day, gabapentin 
3 × 200 mg t.i.d. for slow dose reduction and withdrawal.
It should be bear in mind that neuropathic pain, after 
controlling the dominant visceral pain, may be subjectively 
perceived as stronger (it begins to dominate) and reported 
as “more troublesome”.
Discussion
In case of neuropathic pain, the plasticity of the ne-
rvous system causes pain to feel without a noticeable pain 
stimulus, so-called the phenomenon of spontaneous pain, 
or a painful response to the stimulus that does not usually 
provoke pain (allodynia), or increased pain from a stimulus 
that usually provokes pain and (hyperalgesia).
One of the mechanisms is sensitization at the level of 
the spinal cord and the upper levels of the CNS. Among the 
inhibitory mechanisms, the descending pathways, begin-
ning in the midbrain and the medulla are important. They 
can inhibit or support the transmission of pain in the spinal 
cord. Serotonin and noradrenaline (NA) are important neu-
rotransmitters. A painful stimulus may initiate a reversible 
reaction and the release of NA binding to alpha2 adrenergic 
receptors [14, 15].
The serotonergic pathway of the descending pain inhi-
bition system can facilitate or inhibit impulses conduction 
across the various 5-HT receptor subtypes. Under normal 
conditions, constant descending and α2 adrenoceptor in-
hibition occurs.
At the time of nerve damage, conduction by descending 
path is increased. This phenomenon explains the lack of 
efficacy of selective serotonin reuptake inhibitor (SSRIs) in 
the treatment of chronic neuropathic pain. SSRIs indirectly 
cause simultaneous activation of inhibition as well as stim-
ulation of 5-HT receptors [10].
Tapentadol (deprived of serotonin action), increasing 
the activity of descending noradrenergic pain inhibition 
pathways and simultaneously by activating opioid receptors 
inhibiting the ascending pathways of pain in the CNS, seems 
to be an interesting drug for the treatment of neuropathic 
pain syndromes [18]. The drug is slightly bound to plasma 
proteins, about 20%, which reduces the risk of interaction 
in the mechanism of protein binding. Inactive metabolites 
also do not cause adverse drug interactions. A small degree 
of microsomal metabolism through CYP enzymes minimizes 
the risk of interaction [11].
Neurolysis of the celiac plexus is performed mainly in 
cases of visceral pain located in the epigastrium caused 
by pancreatic, gastric and liver cancer and spread to the 
retroperitoneal lymph nodes. It is also performed in the 
case of pain related to chronic pancreatitis. The best effect 
is obtained if the tumor is located in the tail of the pancreas.
In the majority of patients, after the neurolysis procedu-
re, the basic pain decreases or disappears, but the breakth-
rough pain remains in lower intensity. It is most often similar 
to primary pain and has an average of 2.7 points. Patients 
after neurolysis achieve better pain reduction, manifested by 
lower opioid consumption, reduced side effects of opioids 
and better quality of life [19].
In patients with nausea, vomiting or dysphagia, trans-
dermal preparations of fentanyl and buprenorphine are an 
alternative to opioids administered s.c. or i.v. [1, 2].
Chemotherapy-induced polyneuropathy (CIPN) is a 
common side effect of chemotherapy. Oxaliplatin deriva-
tives belong to the substance with the highest induction 
rate of polyneuropathy. Currently no consistent caring 
standard is available in the treatment of CIPN. Guidelines 
for the treatment of neuropathic pain should be followed. 
The drugs of choice according to currently available studies 
are: gabapentin, pregabalin, duloxetine, gels with baclofen 
(not available in Poland), amitriptyline [20]. The dual mecha-
nism of action of tapentadol allows for consideration of the 
drug in CIPN therapy. The use of tapentadol is associated 
with low interaction risk. A good tolerance profile facilitates 
titration and rotation. Further research is needed to assess 
whether tapentadol may be considered as monotherapy or 
in combination with an adjuvant in the treatment of CIPN.
Summary
About 80% of patients with advanced pancreatic cancer 
suffer from severe and very severe pain, which requires 
intensive treatment. Pain in most cases is mixed in nature. 
Unrecognized neuropathic pain in the course of pancreatic 
diseases is a frequent cause of incorrect selection of drugs. 
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Achieving good pain control is one of the most important 
goals of palliative care. The administration of adequately 
high doses and the appropriate opioid (in the adjuvant 
setting) may be hindered by their poor tolerance and the 
inability to achieve an effective dose.
In case of no analgesic effect, it is recommended to 
replace one opioid to another (so-called rotation), in total 
or partial rage, adding another adjuvant drug, providing an 
effective method of relieving breakthrough pain (the right 
drug, the right dose and route of administration for a quick 
analgesic effect). Whenever the clinical situation requires, 
changing the route of drug administration from oral to par-
enteral s.c./i.v., TTS is recommended. Opioid pharmacology 
is complex, and the individual effect is the resultant of many 
factors. If pharmacological methods are not sufficiently ef-
fective, one should use interventional (procedure) methods 
of pain management [1, 2, 4].
Neurolysis of the celiac plexus does not always com-
pletely reduce pain. It causes a significant reduction in the 
intensity of basic pain, helping to reduce opioid doses, re-
ducing the intensity of side effects and improving patients 
quality of life. The analgesic effect lasts about 2–3 months.
The treatment does not prevent the occurrence of break-
through pains which require separate treatment [17, 19].
Most cancer patients experience mixed pain (74%) as 
the disease progresses. Taking into account the different 
mechanisms of nociceptive and neuropathic pain, μ agonists 
and drugs blocking the secondary uptake of NA are used 
in the treatment [5].
Tapentadol is the only centrally acting opioid that com-
bines these two mechanisms of action — mi receptor ago-
nists (MORs) and norepinephrine reuptake inhibitors (NRIs). 
The specificity of tapentadol makes it highly effective in the 
treatment of severe mixed pain as well as neuropathic pain 
syndromes. Its use also results in the possibility of opioid saving 
(opioid-sparing effect). The simultaneous action of MOR and 
NRI mechanism contributes to the final analgesic effect, allow-
ing the use of lower doses to achieve a given level of analgesia 
[10]. The double mechanism provides effective antinociceptive 
action and alleviation of hyperalgesia and allodynia [9].
Tapentadol has a more favorable profile of side effects. 
Significantly less gastrointestinal adverse events were ob-
served in the conducted studies compared to fentanyl, mor-
phine and oxycodone. A favorable pharmacokinetic profile 
contributes to a small number of discontinuations due to 
poor tolerability or side effects. Because tapentadol does not 
show significant serotonergic activity, there is no risk of side 
effects typical for SSRI, including serotonin syndrome [6].
Long-term use of tapentadol has a slower effect on 
tolerability compared to morphine [8]. A synergistic, dual 
mechanism of action and the effect of saving opioids can 
increase the effectiveness of treatment by improving com-
pliance (regularity of use) [8]. The efficacy of tapentadol 
in the treatment of mixed and neuropathic cancer pain, 
including CIPN, requires further investigation.
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